The board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 HKD | -1.05% | -4.47% | -4.86% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.86% | 1.85B | |
+34.35% | 705B | |
+31.08% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.06% | 238B | |
-3.48% | 210B | |
+10.04% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market